Colin Reisner - Concepedia

Author

Colin Reisner

AstraZeneca (United States)ORCID

Also Known As

C Reisner, C. REISNER, C. Reisner, C.C. Reisner, COLIN REISNER, Colin Reisner, Reisner C, Reisner,Colin, Strom, Shannon

179

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)Cornell University German Center for Lung Research AstraZeneca (Sweden)LungenClinic Grosshansdorf

About

Colin Reisner is an author at AstraZeneca (United States) specializing in medicine, pulmonary medicine, and pulmonary disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	1.4K
2	Allergy	5	5	482
3	Engineering	1	1	31
4	Health Sciences	1	1	84
5	Allergy Medicine	1	1	16

Colin Reisner

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD Klaus F. Rabe, Fernando J. Martinez, Gary T. Ferguson, New England Journal of Medicine	2020	635
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial Gary T. Ferguson, Klaus F. Rabe, Fernando J. Martínez, The Lancet Respiratory Medicine Translational MedicinePulmonary CareAdvanced Lung DiseaseTriple TherapyPulmonary Pharmacology	2018	388
The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD Nicola A. Hanania, Patrick Darken, Donald H. Horstman, CHEST Journal Pulmonary CareAllergyAdvanced Lung DiseaseMedicineFluticasone Propionate	2003	327
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study Fernando J. Martínez, Klaus F. Rabe, Gary T. Ferguson, American Journal of Respiratory and Critical Care Medicine	2020	244
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β <sub>2</sub> -Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE <sup>2</sup> SPOND). A Randomized Clinical Trial Fernando J. Martínez, Klaus F. Rabe, Sanjay Sethi, American Journal of Respiratory and Critical Care Medicine	2016	121
Cardiovascular Safety of Salmeterol in COPDa Gary T. Ferguson, Christian Funck‐Brentano, Tracy Fischer, CHEST Journal Pulmonary CirculationCardiovascular DiseaseCardiovascular SafetyMedicineCardiology	2003	106
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD Fernando J. Martínez, Klaus F. Rabe, Gary T. Ferguson, CHEST Journal Pulmonary CareAdvanced Lung DiseasePulmonary MedicineMedicinePulmonary Disease	2016	102
The Combination of Ipratropium and Albuterol Optimizes Pulmonary Function Reversibility Testing in Patients With COPD Paul Dorinsky, Colin Reisner, Gary T. Ferguson, CHEST Journal AsthmaAdvanced Lung DiseasePulmonary MedicineMedicinePulmonary Disease	1999	90
DO VITAMIN D SUPPLEMENTS IMPROVE THE PHYSICAL CAPABILITIES OF ELDERLY HOSPITAL PATIENTS? D. Corless, Erica Dawson, F C Fraser, Age and Ageing AgingHealth SciencesHealthy AgingGeriatricsDementia	1985	84
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial Jean Chastre, Bruno François, Marc Bourgeois, Critical Care	2022	82

Page 1